Malik Benamar
Novo Nordisk (Denmark)(DK)
Publications by Year
Research Areas
Diabetes Treatment and Management, Diabetes Management and Research, Diabetes and associated disorders, Diabetes Management and Education, Metabolism, Diabetes, and Cancer
Most-Cited Works
- → Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial(2025)15 cited
- → Improved treatment satisfaction with once-weekly insulin icodec compared with once-daily basal insulin in individuals with type 2 diabetes: An analysis of patient-reported outcomes and participant interviews from ONWARDS 2 and 5 and a physician survey from ONWARDS 1(2024)6 cited
- → Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant‐level analysis of the ONWARDS 1–5 trials(2025)3 cited
- → Correction: Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial(2025)2 cited
- → 826-P: Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Individuals with Type 2 Diabetes by Kidney Function—ONWARDS 1–5(2024)1 cited
- → 804-P: A1C and Hypoglycemia Outcomes with Once-Weekly IcoSema vs. Comparators in T2D by Kidney Function(2025)
- → Efficacy and Safety of Once-Weekly IcoSema Versus Once-Daily IDegLira in People with Type 2 Diabetes: Systematic Literature Review and Network Meta-analysis(2026)
- → Author response for "Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant‐level analysis of the <scp>ONWARDS</scp> 1–5 trials"(2025)